ScreenIT
The Automated Screening Working Groups is a group of software engineers and biologists passionate about improving scientific manuscripts on a large scale. Our members have created tools that check for common problems in scientific manuscripts, including information needed to improve transparency and reproducibility. We have combined our tools into a single pipeline, called ScreenIT. We're currently using our tools to screen COVID preprints.
Latest preprint reviews
-
Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis
This article has 4 authors:Reviewed by ScreenIT
-
Reacting to outbreaks at neighboring localities
This article has 3 authors:Reviewed by ScreenIT
-
CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants
This article has 10 authors:Reviewed by ScreenIT
-
The Wood equation allows consistent fitting of individual antibody-response profiles of Zika virus or SARS-CoV-2 infected patients
This article has 12 authors:Reviewed by ScreenIT
-
Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic
This article has 7 authors:Reviewed by ScreenIT
-
Coordinated support for local action: Modeling strategies to facilitate behavior adoption in urban-poor communities of Liberia for sustained COVID-19 suppression
This article has 5 authors:Reviewed by ScreenIT
-
Quantifying the impact of quarantine duration on COVID-19 transmission
This article has 5 authors:Reviewed by ScreenIT
-
Fear of COVID-19 Higher among Food-Insecure Households: A Model-Based Study, Mediated by Perceived Stress among Iranian Populations
This article has 5 authors:Reviewed by ScreenIT
-
Mortality and risk factors among US Black, Hispanic, and White patients with COVID-19
This article has 4 authors:Reviewed by ScreenIT
-
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
This article has 10 authors:Reviewed by ScreenIT